]>
IRCT20211003052661N1 IRCT 2021-10-14 Personal Evaluation of the effect of Sakarya-20 in the treatment of Covid disease - 19 Evaluation of safety and antiviral effect of Sakarya-20 inhaled solution containing fuzzy nanoparticles on the recovery of patients with Covid-19 2022-02-28 anticipated 14 Complete https://irct.ir/trial/59198 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 0 (exploratory trials) COVID-19. Intervention group: Patients take Sakarya-20 pharyngeal inhalation solution along with standard treatments. Sakarya-20 contains: a complex of nanoparticles (gold, silver and iron) with a total concentration of 40 ppm soluble in water manufactured by Hayyan pharmaceutical company. The method of administration is that the patient first inhales 0.5 cc every 8 hours for two days, and from the third to the ninth day 0.5 cc solution once a day.. Yes - There is a plan to make this available What will be shared: Part of the data, such as information about the main outcome or the like, can be shared. When: 15 days after the publication of the article To whom: Specialists and researchers in the field of health and medicine Conditions: The use of documents will be allowed by mentioning the source. Where to obtain: To Dr. Ali Maleki ali.malaki2775@gmail.com How to obtain: Investigation and verification of the applicant, and the applicant request Comments:
public Amir Rezazadeh
Simon Bolivar Farhikhtegan Hospital
Tehran Iran (Islamic Republic of) 1996835113 +98 912 729 8761 amirrezazadeh251@gmail.com Azad University, Tehran Medical Sciences Branch scientific Amir Hossein Moghtadar Mozhdehi
Azad University, Medical Sciences Branch
tehran Iran (Islamic Republic of) 5661984196 +98 45 3253 4518 amirtxt@yahoo.com Islamic Azad University Iran (Islamic Republic of) Admission of Covid-19 patients over 18 years of age who are diagnosed based on a number of clinical coronary symptoms (dry cough, fever, headache, sore throat, lymphopenia or thrombocytopenia) by a physician and confirmed by PCR-viral diagnostic test load test (swallowing of the throat and nose) is performed in the laboratory. COVID-19 patients with mild to moderate disease who do not need to be admitted to the coronary ward (no lung involvement or very little involvement confirmed by CT scan) are included in the study if they are satisfied. 18 years no limit Both Age under 18, Lung involvement (need to be hospitalized), malignant tumor and other acute systemic diseases, co-infection with HIV, tuberculosis, history of asthma, asthma-like attacks and respiratory problems, life-threatening comorbidity Consumption of any other pharyngeal inhaler, pregnancy and lactation U07.1 COVID-19, virus identified Treatment - Drugs Intervention group: Patients take Sakarya-20 pharyngeal inhalation solution along with standard treatments. Sakarya-20 contains: a complex of nanoparticles (gold, silver and iron) with a total concentration of 40 ppm soluble in water manufactured by Hayyan pharmaceutical company. The method of administration is that the patient first inhales 0.5 cc every 8 hours for two days, and from the third to the ninth day 0.5 cc solution once a day. Virus clearance. Timepoint: Before and after intervention. Method of measurement: Polymerize chain reaction test using thermocycler. Percentage of oxygen saturation. Timepoint: Before and after the intervention. Method of measurement: Oximeter. Clinical symptoms changes. Timepoint: Before and after the intervention. Method of measurement: Questionnaire. Personal Approved 2021-09-28 Research Ethics Committee of the Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Azad Univer Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Azad University of Medical Sciences Tehran Tehran Iran (Islamic Republic of)